Literature DB >> 26341256

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model.

Tobias Tritschler1, Marie Méan2, Andreas Limacher3, Nicolas Rodondi1, Drahomir Aujesky1.   

Abstract

The updated Vienna Prediction Model for estimating recurrence risk after an unprovoked venous thromboembolism (VTE) has been developed to identify individuals at low risk for VTE recurrence in whom anticoagulation (AC) therapy may be stopped after 3 months. We externally validated the accuracy of the model to predict recurrent VTE in a prospective multicenter cohort of 156 patients aged ≥65 years with acute symptomatic unprovoked VTE who had received 3 to 12 months of AC. Patients with a predicted 12-month risk within the lowest quartile based on the updated Vienna Prediction Model were classified as low risk. The risk of recurrent VTE did not differ between low- vs higher-risk patients at 12 months (13% vs 10%; P = .77) and 24 months (15% vs 17%; P = 1.0). The area under the receiver operating characteristic curve for predicting VTE recurrence was 0.39 (95% confidence interval [CI], 0.25-0.52) at 12 months and 0.43 (95% CI, 0.31-0.54) at 24 months. In conclusion, in elderly patients with unprovoked VTE who have stopped AC, the updated Vienna Prediction Model does not discriminate between patients who develop recurrent VTE and those who do not. This study was registered at www.clinicaltrials.gov as #NCT00973596.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26341256     DOI: 10.1182/blood-2015-04-641225

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.

Authors:  Joie Ensor; Richard D Riley; David Moore; Kym I E Snell; Susan Bayliss; David Fitzmaurice
Journal:  BMJ Open       Date:  2016-05-06       Impact factor: 2.692

2.  Association of recurrent venous thromboembolism and circulating microRNAs.

Authors:  Xiao Wang; Kristina Sundquist; Peter J Svensson; Hamideh Rastkhani; Karolina Palmér; Ashfaque A Memon; Jan Sundquist; Bengt Zöller
Journal:  Clin Epigenetics       Date:  2019-02-13       Impact factor: 6.551

3.  Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP).

Authors:  Jasmijn F Timp; Sigrid K Braekkan; Willem M Lijfering; Astrid van Hylckama Vlieg; John-Bjarne Hansen; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter
Journal:  PLoS Med       Date:  2019-10-11       Impact factor: 11.069

Review 4.  From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.

Authors:  Larisa Anghel; Radu Sascău; Rodica Radu; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

Review 5.  Predicting the risk of recurrent venous thrombosis: What the future might bring.

Authors:  Willem M Lijfering; Jasmijn F Timp; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2019-07-16       Impact factor: 5.824

6.  Risk prediction of recurrent venous thrombosis; where are we now and what can we add?

Authors:  Jasmijn F Timp; Willem M Lijfering; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2019-07-04       Impact factor: 5.824

7.  Prediction models for venous thromboembolism in ambulatory adults with pancreatic and gastro-oesophageal cancer: protocol for systematic review and meta-analysis.

Authors:  Asma Zaheer; Nenad Naumovski; Kellie Toohey; Theophile Niyonsenga; Desmond Yip; Nicholas Brown; Reza Mortazavi
Journal:  BMJ Open       Date:  2022-03-04       Impact factor: 2.692

Review 8.  Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.

Authors:  Balbir Singh; Paresh Pai; Harish Kumar; Sheeba George; Sandeep Mahapatra; Vineet Garg; G N Gupta; Kiran Makineni; Gaurav Ganeshwala; Pravin Narkhede; Syed M H Naqvi; Kumar Gaurav; Mohammed Y K Hukkeri
Journal:  Cardiol Ther       Date:  2022-02-08

9.  Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception.

Authors:  Magdalena Piróg; Sławomir Piwowarczyk; Anetta Undas
Journal:  Dis Markers       Date:  2019-11-18       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.